rs11942223 — SLC2A9

Intronic SLC2A9 variant tagging an independent urate-transport signal; the protective C allele (~26% global frequency) reduces serum uric acid by 0.23–0.46 mg/dL per copy — with a substantially stronger effect in women — and attenuates the hyperuricemic response to fructose; the major T allele confers elevated uric acid and increased gout risk, particularly in Europeans

See your personal result for SLC2A9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC2A9 Intronic Variant rs11942223 — A Second Independent Signal for Uric Acid Control

Your serum uric acid level is regulated in large part by transporters in your kidneys, and the strongest genetic region for that regulation sits in the SLC2A9 gene. Most people have heard of the coding variant rs3733591 (Arg265His), but the SLC2A9 locus contains a second, genetically independent signal — rs11942223 — that contributes its own effect on urate transport. Understanding which variant you carry matters because their effects are additive, and the intronic signal captured by rs11942223 is the one with the most pronounced sex-specific effect.

SLC2A9 encodes GLUT911 GLUT9
Glucose Transporter 9, a high-capacity urate transporter in the kidney proximal tubule that mediates urate reabsorption; despite its name, it transports urate far more efficiently than glucose. The rs11942223 variant lies within an intron and does not change the protein directly, but it tags a regulatory or structural haplotype that modulates the efficiency of renal urate clearance. This intronic signal is in strong LD with rs12498742, another well-characterised urate-GWAS proxy for the same haplotype block.

The Mechanism

rs11942223 is an intron variant that does not alter the amino acid sequence of GLUT9. Its effect on urate transport is regulatory in nature — it tags a haplotype block within the SLC2A9 gene that influences transporter expression or splicing. The variant explains 1.2% of variance in serum urate in men and up to 6% in women (Döring et al., 2008)22 (Döring et al., 2008), a difference attributed to an interaction with estrogen signalling: estrogen independently stimulates renal urate excretion, which amplifies the apparent genetic effect in women compared to men.

The rs11942223 T allele (major allele, ~74–78% frequency in Europeans) is associated with reduced renal urate excretion and higher steady-state serum uric acid. The C allele (minor allele, ~22–26% in Europeans, rare in Polynesian populations) is protective — each copy reducing serum urate by approximately 0.23–0.36 mg/dL in men and 0.36–0.46 mg/dL in women.

Critically, this signal is independent of rs3733591 (Arg265His). Linkage disequilibrium between rs11942223 and rs3733591 is very low (r² = 0.03–0.05 across Māori, Eastern Polynesian, Western Polynesian, and Caucasian populations), confirming they tag distinct biological mechanisms at the same locus. Carriers of T alleles at both variants carry additive genetic risk for elevated uric acid.

The Evidence

Discovery of the SLC2A9 locus with sex-specific effects: Döring et al. (2008) mapped intronic SLC2A9 variants explaining up to 6% of urate variance in women but only 1.2% in men, making this the first demonstration of a major sex-specific quantitative trait locus for serum urate. The study used KORA German cohort data with independent replication (Döring et al., 2008)33 (Döring et al., 2008).

Multi-ethnic gout association: Hollis-Moffatt et al. (2009) genotyped rs11942223 alongside rs3733591 and two other SLC2A9 variants in Māori, Pacific Island, and Caucasian gout case-control sets. The major (T) allele of rs11942223 was associated with gout across all populations (P = 1.6 × 10⁻⁶ for the combined sample), with odds ratio > 2.0 in Māori and Pacific Island subjects. Crucially, LD between rs11942223 and rs3733591 was r² = 0.03–0.05 — confirming these are independent loci acting in parallel (Hollis-Moffatt et al., 2009)44 (Hollis-Moffatt et al., 2009).

Gene-environment interaction with dietary fructose: A fructose-challenge study in 76 volunteers (25 Māori, 26 Pacific, 25 European Caucasian) found that the C allele (protective) was associated with an attenuated hyperuricemic response and increased fractional excretion of uric acid after a fructose load, but only in the Caucasian subgroup — not in Māori or Pacific participants (Batt et al., 2013)55 (Batt et al., 2013). This suggests the protective haplotype tagged by the C allele has functionally different penetrance across ancestries.

Sugar-sweetened beverages reverse the protective effect: A follow-up study found that the normally urate-lowering C allele reversed its effect under regular sugar-sweetened beverage (SSB) exposure — C allele carriers showed a 15% increase in gout risk per daily SSB serving, compared to 12% in non-carriers (Dalbeth et al., 2014)66 (Dalbeth et al., 2014). This gene-environment interaction is clinically actionable: the C allele's urate-lowering benefit disappears under high fructose load, making SSB avoidance particularly important for carriers of either allele.

Practical Actions

The rs11942223 T allele (major allele) elevates serum urate by reducing renal clearance, and the effect is amplified in women (especially post-menopausal) and by dietary fructose. Since this is an independent signal from rs3733591, carrying T alleles at both variants compounds the urate burden — each locus adds independently to the genetic elevation.

The most effective dietary intervention for T/T homozygotes is eliminating sugar-sweetened beverages (sodas, fruit juices, energy drinks), since fructose both raises urate directly and — for this specific variant — can override the dose-response that would normally moderate the effect. Purine restriction (organ meats, shellfish, beer) remains important. Low-fat dairy, coffee, vitamin C, and adequate hydration all contribute to modest but evidence-supported reductions in serum urate.

Given the pronounced sex-specific effect (~5× larger variance explained in women), women who carry T alleles should have serum uric acid checked at menopause, when the loss of estrogen's uricosuric protection unmasks genetic risk that was previously buffered.

Interactions

Independent from rs3733591 (SLC2A9 Arg265His): The r² between rs11942223 and rs3733591 is only 0.03–0.05 — these variants are effectively unlinked and tag distinct regulatory and coding effects in the same gene. Carrying risk alleles at both compounds the urate elevation additively. Individuals with TT at rs11942223 and CC at rs3733591 carry two independent SLC2A9 risk signals.

SLC2A9 and ABCG2 (rs2231142): ABCG2 Q141K reduces intestinal urate secretion through a completely different pathway. Carrying risk alleles at rs11942223 (renal reabsorption) and ABCG2 rs2231142 (intestinal secretion) is additive and can produce mean serum urate above 7 mg/dL even in healthy individuals without dietary provocation.

Fructose and sugar-sweetened beverages: A documented gene-environment interaction reverses the C allele's protective effect under SSB exposure. This is unique among known urate GWAS variants and means that SSB avoidance is the single most important lifestyle action for this specific genotype.

Sex and menopausal status: The intronic SLC2A9 signal has a substantially larger effect in women (6% of urate variance vs. 1.2% in men), mediated through estrogen's interaction with renal urate handling. Post-menopausal women carrying T alleles lose this hormonal buffer and represent the highest-risk subgroup for this variant.

Nutrient Interactions

fructose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Efficient Urate Clearance Normal

Two protective C alleles — lower uric acid baseline and attenuated fructose response

You carry two copies of the protective C allele at rs11942223. This is the less common genotype globally (roughly 5–7% of people based on Hardy-Weinberg from the ~26% C allele frequency). Each C allele reduces serum urate by approximately 0.3–0.5 mg/dL compared to TT carriers, with the benefit being strongest in women of reproductive age. Your genetic risk for hyperuricemia and gout from this SLC2A9 signal is low, though dietary fructose (from sugar-sweetened beverages) can partially override this advantage. Note that this variant is independent from rs3733591 — your CC status here does not affect your Arg265His genotype.

CT Intermediate Urate Clearance Intermediate

One protective C allele — modest urate reduction, fructose sensitivity relevant

The CT heterozygous state at rs11942223 means one copy of your SLC2A9 transporter regulatory haplotype is the protective form and one is the risk form. The net effect is intermediate renal urate excretion — better than TT on a low-fructose diet, but the advantage narrows with regular sugar intake. Women with CT genotype experience roughly twice the effect size compared to men, making this particularly worth monitoring around menopause when estrogen's uricosuric support diminishes. If you also carry risk alleles at rs3733591 (SLC2A9 Arg265His) or ABCG2 rs2231142, the combined genetic burden on urate clearance is meaningful.

TT Reduced Urate Clearance High Risk

Two T alleles — genetically elevated uric acid with enhanced fructose sensitivity

The TT genotype at rs11942223 means both copies of your SLC2A9 regulatory haplotype are the risk form, resulting in the highest degree of reduced renal urate excretion from this specific signal. Serum urate rises approximately 0.46–0.92 mg/dL above CC carriers — enough to meaningfully shift the probability of exceeding the hyperuricemia threshold (>7 mg/dL in men, >6 mg/dL in women) when combined with dietary purines or other genetic risk variants.

This variant is independent from rs3733591 (Arg265His), with r² only 0.03–0.05 between them. Carrying TT here and CC at rs3733591 means you carry two independent SLC2A9 risk signals, each elevating urate through distinct mechanisms. Similarly, adding ABCG2 rs2231142 risk alleles (intestinal urate secretion pathway) creates a three-locus compounded risk that can push serum urate above 7 mg/dL in otherwise healthy individuals.

The fructose interaction is clinically important: sugar-sweetened beverage consumption raises urate through direct fructose metabolism and also appears to amplify genotype-specific effects at the SLC2A9 locus, with studies showing a 12–15% per-daily-serving increase in gout risk that is modulated by SLC2A9 genotype.